ADD/ADHD News

The Healio news staff received an APEX award in the category of Writing/Topics for work on the potential role of psychedelics and alternative therapies for mental health issues and other medical conditions.

Many factors have contributed to the recent surge in adult ADHD diagnoses, but the rise is mostly reflective of what has always existed and gone undetected, according to experts.

The FDA has approved Onyda XR extended-release oral suspension for the treatment of ADHD among children aged 6 years and older, according to a press release from Tris Pharma, Inc.

Approximately one in nine children in the United States had ever received an ADHD diagnosis as of 2022, according to research published in the Journal of Clinical Child & Adolescent Psychology.

However, the prevalence of cardiomyopathy in this population was less than 1%.

A systematic review of hundreds of studies showed that medication has the best chance to improve ADHD outcomes in children and that other treatments have varied effects, according to results published in Pediatrics.

Researchers identified differences in resting-state subcortico-cortical connectivity between youth with and without ADHD by analyzing almost 10,000 functional brain images, according to data published in The American Journal of Psychiatry.

SAN DIEGO — Children with vs. without atopic dermatitis are more likely to experience learning and memory difficulties, according to a poster presented at the American Academy of Dermatology Annual Meeting.

In utero exposure to amphetamine/dextroamphetamine or methylphenidate was not associated with increased risks for neurodevelopmental disorders in children, according to cohort study results published in JAMA Psychiatry.